Hawthorn Catrin
CMATS Carmarthenshire, Glangwilli General Hospital, Hywel Dda University Health Board, Carmarthen, UK.
Rehabil Process Outcome. 2020 Jun 11;9:1179572720914945. doi: 10.1177/1179572720914945. eCollection 2020.
The use of the topical nonsteroidal anti-inflammatory drugs (NSAID) ibuprofen for the treatment of knee osteoarthritis. Supporting clinician decision-making in the first-line treatment of osteoarthritis.
To open discussion at a clinical level on the guidelines for the pharmacological management of osteoarthritis of the knee, this narrative review looks into the use of topical NSAID being a clinically effective, safe, and cost-efficient treatment compared to an oral alternative.
With the over prescription of NSAIDs in the age of above 65 years, there has been a call for increased restrictions of the sale of oral preparations of NSAIDs. It is our view that there is still a lack of awareness in the benefit of topical NSAIDs to the patient (no evidence of adverse reactions recorded by the Joint Formulary Committee [JFC] to date) as well as provider (topical application is cheaper as a National Health Service [NHS] prescription).
Key online resources included PubMed, Athens, Cochrane Library, Google Scholar, MEDLINE, and relevant clinical and commissioning guidelines with the final date of data collection in March 2017. We also contacted the manufacturer and license holder directly for further clarification. Randomized, double-blind control studies, commissioned reports, International Guidelines, MEHA Guidelines, and license holder data were included. Where possible studies included had to have fair randomization and adhere to key treatment pathways as highlighted by National Institute for Health and Clinical Excellence (NICE) and other guidelines.
Current guidelines advise that patients who seek initial treatment of osteoarthritis of the knee should consider a combination of treatment modalities, including pharmacological therapies, particularly the use of NSAIDs. At a clinical level, a reoccurring issue identified with this advice is the inappropriate use of oral NSAIDs, and the concern that the risks associated with ease of access ("over the counter"), and overuse, may result in systemic adverse events in this cohort of patients. Multiple studies have examined the negative effect of oral NSAIDs and the associated risks of use. We were unable to source studies that showed any adverse systemic events from the use of topical NSAIDs; however, there are good quality trials comparing oral to topical NSAIDs, showing similar levels of efficacy at 6 and 12 weeks.
Topical NSAIDs provide good levels of pain relief in subjects with mild to moderate knee osteoarthritis. There is also evidence for the use of the topical application being a clinically effective, safe, and cost-efficient treatment.
局部使用非甾体抗炎药(NSAID)布洛芬治疗膝关节骨关节炎。支持临床医生对骨关节炎一线治疗的决策。
为了在临床层面就膝关节骨关节炎的药物治疗指南展开讨论,本叙述性综述探讨了与口服药物相比,局部使用NSAID是一种临床有效、安全且经济高效的治疗方法。
在65岁以上人群中,NSAIDs存在过度处方的情况,因此有人呼吁加强对NSAIDs口服制剂销售的限制。我们认为,患者(截至目前联合处方委员会[JFC]未记录到不良反应证据)以及医疗服务提供者(作为英国国家医疗服务体系[NHS]处方,局部用药更便宜)对局部使用NSAIDs的益处仍缺乏认识。
主要在线资源包括PubMed、Athens、Cochrane图书馆、谷歌学术、MEDLINE以及相关临床和委托指南,数据收集截止日期为2017年3月。我们还直接联系了制造商和持牌人以获取进一步的说明。纳入随机、双盲对照研究、委托报告、国际指南、MEHA指南和持牌人数据。纳入的研究在可能的情况下必须有合理的随机分组,并遵循英国国家卫生与临床优化研究所(NICE)及其他指南强调的关键治疗途径。
当前指南建议,寻求膝关节骨关节炎初始治疗的患者应考虑多种治疗方式的组合,包括药物治疗,特别是使用NSAIDs。在临床层面,这一建议中反复出现的问题是口服NSAIDs的不当使用,以及对因易于获取(“非处方药”)和过度使用而带来的风险可能导致该类患者出现全身不良事件的担忧。多项研究已考察了口服NSAIDs的负面影响及相关使用风险。我们未能找到显示局部使用NSAIDs会导致任何全身不良事件的研究;然而,有高质量的试验比较了口服和局部使用NSAIDs,结果显示在6周和12周时疗效水平相似。
局部使用NSAIDs能为轻度至中度膝关节骨关节炎患者提供良好的疼痛缓解效果。也有证据表明局部用药是一种临床有效、安全且经济高效的治疗方法。